$742 Million is the total value of Sarissa Capital Management LP's 11 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALKS | Sell | ALKERMES PLC | $197,252,022 | -55.1% | 7,042,200 | -49.8% | 26.57% | -39.3% |
| BIIB | BIOGEN INC | $165,257,430 | -9.8% | 643,000 | 0.0% | 22.26% | +22.1% | |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $157,835,700 | -9.5% | 16,390,000 | 0.0% | 21.26% | +22.5% | |
| INVA | INNOVIVA INC | $94,528,230 | +2.0% | 7,277,000 | 0.0% | 12.73% | +38.1% | |
| GILD | GILEAD SCIENCES INC | $68,974,776 | -2.8% | 920,400 | 0.0% | 9.29% | +31.6% | |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $41,175,000 | +88.8% | 366,000 | +58.2% | 5.55% | +155.5% |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $9,607,057 | +64.4% | 10,442,453 | +112.7% | 1.29% | +122.3% |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $5,487,000 | +0.6% | 775,000 | 0.0% | 0.74% | +36.1% | |
| VOR | VOR BIOPHARMA INC | $1,310,160 | -31.4% | 618,000 | 0.0% | 0.18% | -7.4% | |
| MRSN | Sell | MERSANA THERAPEUTICS INC | $698,500 | -91.9% | 550,000 | -79.1% | 0.09% | -89.1% |
| REGULUS THERAPEUTICS INC | $253,701 | -6.8% | 185,183 | 0.0% | 0.03% | +25.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.